In the case of IL-6 or IL-22, it prevents fibrogenesis but promotes hepatocellular carcinoma, so the risk of tumor occurrence should be considered in the treatment of patients with hepatic fibrosis (Schmidt-Arras and Rose-John, 2016; Wu et al., 2020). This evidence concerns the gene IL6 and hepatocellular carcinoma.